

# AD HOC: ACQUISITION OF OWN SHARES OF NEXUS AG

## Ad hoc News in accordance with paragraph 15 WpHG

Donaueschingen, 25 October 2016: With the consent of the Supervisory Board today, the Executive Board of NEXUS AG (WKN 522090/ISIN DE0005220909) has resolved to exercise the authorization granted by the Annual General Meeting of 18 May 2015 to purchase up to 200,000 of its own shares (representing 1.27% of share capital) of the company pursuant to Section 71 para. 1 No. 8 of the Stock Corporation Act (AktG). The authorization is restricted to the time period until 30 April 2020 and limited to 10% of the equity capital. The resolution of the Executive Board is designed for the purpose of purchasing own shares of the company one time or several times in line with market conditions and within the context of the Board's authorization to do so.

According to the authorization of the Annual General Meeting, if stocks are purchased directly via the securities market, the paid equivalent value per share (excluding incidental purchase costs) may not exceed the average price of the closing rates in XETRA trade (or a comparable follow-up system) at the Frankfurt/Main Securities Market for the stocks of the company during the last five stock market days before purchase of the stocks by more than 10% nor may they be more than 10% below these prices.

The share buyback will be managed by a bank and start on 25 October 2016. The credit institution shall make decisions on the date of acquisition and the amount of individual repurchase of shares of NEXUS AG independently and uninfluenced by NEXUS AG.

NEXUS AG will announce transactions exercised as part of the share buyback regularly via a European-wide information dissemination system and on its website in the area of Investor Relations ([www.nexus-ag.de](http://www.nexus-ag.de) – Investor Relations – Share Buyback).

## ABOUT NEXUS AG

NEXUS AG is a software vendor specialized in eHealth solutions. NEXUS software helps hospitals, psychiatric and rehabilitation clinics to increase efficiency and safety in treating patients. A total of almost 930 staff members at NEXUS develop solutions for approx. 196,300 users in 19 countries.